Cancer treatment relies on averages, but patients aren't average. Molecular tumor boards analyze thousands of data points per patient to design personalized regimens, going far beyond the limited biopsy and imaging data standard oncology uses.
We understand that the conventional model likes to adhere to the one size fits all, double blind placebo clinical trial, but that isn't you. Everybody's not the average. And the integrative medicine, which is doing the best they can to support healing, is trying to give you energy and fuel for recovery. But it also may not be as precise as you need it. So this is why we're talking about today, this n of 1. What is n of 1? It's the treatment built on you and everything around the treatment. The data is on you. N of 1 treatment. We have molecular tumor boards that meet regularly and we talk about this all the time. Like two cancer patients, two types, two stages, totally different treatments. Because we're looking at a thousand data points and conventional oncology might be looking at two dozen. Biopsy, tumor marker imaging, that's it. You fail a treatment, go to the next regimen, fail a treatment, that's it. It's not at the level of looking at these thousand plus data points to really dial in the treatment specifically for each patient.
